Multiple myeloma: therapeutic delivery of antibodies and aptamers

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A. , Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S. and Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12(10), pp. 705-722. (doi: 10.4155/tde-2021-0041) (PMID:34569269)

Full text not currently available from Enlighten.

Abstract

Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.

Item Type:Articles
Additional Information:This research was funded by the BBSRC-funded DTP IBioIC, grant number BB/S507118/1.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Horne, Dr Gillian and Soutar, Dr Richard
Authors: Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A., Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S., and Mulheran, P. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Therapeutic Delivery
Publisher:Future Sciences Group
ISSN:2041-5990
ISSN (Online):2041-6008
Published Online:27 September 2021

University Staff: Request a correction | Enlighten Editors: Update this record